Introduction
Chronic bacterial respiratory infection is the leading cause of death in cystic fibrosis (CF) (1) . As CF patients are living longer, respiratory tract colonization and infection with multi-drug resistant pathogens are increasing in frequency. Among these, Stenotrophomonas maltophilia is one of the more common, isolated from the respiratory tract of up to 30% of CF patients(2) (3).
It is unclear whether S. maltophilia simply colonizes the airway or causes true infection and clinical decline in CF. Epidemiologic studies have not shown any association between S. maltophilia and survival or declining lung function in CF (4, 5) . However, these studies focused on CF patients who were positive at any point in time for S. maltophilia and did not make the distinction between chronic and intermittent isolation of S. maltophilia in the respiratory tract.
As has been shown with methicillin-resistant Staphylococcus aureus (MRSA) and Aspergillus fumigatus, chronic infection with S. maltophilia may be more likely to cause clinical deterioration in CF (6) (7) (8) .
The aim of this study was to determine the impact of S. maltophilia infection on lung disease in CF. Chronic infection with an organism can be defined by the number or percentage of positive cultures of respiratory specimens in a given year. This strategy has been validated for Pseudomonas aeruginosa infection (9). In addition, chronic exposure to an organism can stimulate an immune response and assessing the immune response can help to distinguish between transient colonization and infection. In the first part of this study, we developed a novel serologic assay specific for S. maltophilia and measured serum antibodies to S. maltophilia in CF patients to determine if a definition of chronic S. maltophilia isolation based on culture results corresponded to an immunologic response. In the second part of the study, we used this Page 4 of 36 validated definition to examine the effect of chronic S. maltophilia on the severity of lung disease as measured by pulmonary function tests (PFTs) and number of acute pulmonary exacerbations in a larger retrospective cohort study in CF patients.
Methods

I. Serologic Study
Study Design
This was a cross-sectional study of CF patients followed at the Hospital for Sick Children and St Michael's Hospital (Toronto, Canada). Patients were excluded if they could not produce sputum, were unable to perform reproducible spirometry or had received a lung transplant. A serum sample was collected for each patient with routine clinical blood sampling in the CF clinic.
Pulmonary function testing was performed on the same day as serum specimens were obtained in 94% of patients (within 3 months in remainder).
Microbiological Classification
All subjects were classified according to their respiratory culture status in the previous 12 months (8): 1) Chronic S. maltophilia: > 2 positive sputum or bronchoalvealar cultures for S. maltophilia in a given year, 2) Intermittent S. maltophilia: 1 positive culture for S. maltophilia in a given year or a previous positive culture, 3) Never S. maltophilia: never having a positive culture for S. maltophilia. Subjects who never had S. maltophilia were divided into those who had chronic P. aeruginosa and those without chronic P. aeruginosa. These definitions were validated against the serologic results.
Sera Processing and Serologic Assay
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Serologic responses were measured by an enzyme-linked immunosorbent assay (ELISA) using 3 S. maltophilia antigens individually (flagellin (10) , protease (11) and whole bacterial cell(12)) (additional details available in online data supplement at www.atsjournals.org). Results were represented as the ratio of the average serum sample optical density (OD) to the average OD value of the 2 negative controls (wells with pooled normal human serum) (Ratio Units: RU).
Statistical Analysis
Analysis of variance (ANOVA) was used to assess if there were significant differences between groups. Correlation analysis was done using Pearson's correlation. Multiple regression analysis was also done on forced expiratory volume in 1 second (FEV 1 ) % predicted and the mean antibody levels adjusting for age, P. aeruginosa and Burkholderia cepacia complex infection.
II. Cohort Study
Study Design
This was a retrospective cohort study from 1997 to 2008 using the Toronto CF Database.
Patients with chronic S. maltophilia were compared to those who had intermittent S. maltophilia and those who did not have S. maltophilia over the study period. The primary outcome measure was the rate of decline of FEV 1 in percent predicted in patients in each of these three groups. The secondary outcome was the number of hospital admissions for pulmonary exacerbations requiring antibiotics per year. The same exclusion criteria and microbiologic classification were used as above.
Statistical Analysis
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Two separate regression models were generated as used in a previous study (8) . In the first model, a hierarchical linear model was generated to look at the effect of chronic S. maltophilia on quarterly FEV 1 allowing for a random effect and slope for each patient. The second model assessed the effect of chronic S. maltophilia on the number of hospitalizations for pulmonary exacerbation requiring antibiotics using Poisson regression. Multivariable analysis was performed to account for potential confounding variables (additional details available in online data supplement at www.atsjournals.org). The Research Ethics Board at the Hospital for Sick Children and St Michael's Hospital approved the studies.
Results
Serology Patient Characteristics and Antibody Levels
Sera were obtained and S. maltophilia antibody levels were measured for 179 CF patients.
Patient characteristics at the time of serologic testing are summarized in Table 1 . Patients with chronic S. maltophilia isolation were significantly older, had lower mean FEV 1 % predicted and were not co-infected with B. cepacia complex. Figure 1 illustrates the mean antibody levels to S. maltophilia flagellin ( Figure 1A ), whole cell ( Figure 1B ) and extracellular protease (Figure 1C) in patients with chronic, intermittent and in those who never had S. maltophilia (subdivided into those who had chronic P. aeruginosa and those without chronic P. aeruginosa). Patients with chronic S. maltophilia had significantly higher mean antibody levels to S. maltophilia flagellin (p<0.0001) and whole cell (p=0.0004), but not to protease, compared to patients with intermittent or no S. maltophilia. Mean antibody levels to flagellin and whole cell were 1.5 times higher in the chronic group compared to the intermittent group and approximately 2 times higher in the chronic group compared to the negative group. There was also no evidence of cross-reactivity of antibodies to S. maltophilia with antibodies to P. aeruginosa as mean antibody levels in patients with chronic P. aeruginosa infection were similar to those in S. maltophilia negative patients.
Antibody Levels and Pulmonary Function
The relationship between antibody levels and FEV 1 percent predicted was then examined. There was a significant inverse correlation between mean flagellin antibody levels and FEV 1 % predicted (p=0.0061) (Figure 2) 
Pulmonary Function
The mean number of years of patient follow up was 8.3 years. In an adjusted model, the rate of decline in FEV 1 % predicted was -1.02% pred/year for patients with chronic S. maltophilia (p=0.3 compared to those who never had S. maltophilia), -0.94% pred/year for patients with intermittent S. maltophilia and -1.06% pred/year for patients who never had S. maltophilia. Figure 3 illustrates the adjusted FEV 1 % predicted over time for patients with chronic, intermittent and those who never had S. maltophilia infection, demonstrating similar rates of pulmonary decline.
Pulmonary Exacerbations
The effect of chronic S. maltophilia infection on the number of pulmonary exacerbations requiring hospitalization and antibiotics per year was evaluated using a log linear model. In an unadjusted model, patients with chronic S. maltophilia infection (RR=2.5, p<0.0001) and patients with intermittent S. maltophilia infection (RR=1.85, p=0.0002) had a significantly increased risk of pulmonary exacerbation compared to patients who had never had S. maltophilia. Nonsignificant variables were then removed and a reduced model was generated adjusting for age, pancreatic insufficiency, P. aeruginosa, BMI and baseline FEV 1 % predicted.
In this model, patients with chronic S. maltophilia infection still had a significantly increased risk of pulmonary exacerbation (RR=1.63, p=0.0002) compared to patients who had never had S. maltophilia but patients with intermittent S. maltophilia infection no longer had a significantly 
Discussion
To our knowledge, this is the first study demonstrating that CF patients with chronic S. maltophilia infection have a specific immune response to S. maltophilia that is associated with lower lung function. We have also shown that chronic S. maltophilia infection is an independent risk factor for pulmonary exacerbation requiring hospitalization and antibiotic therapy. This association was not observed in patients with intermittent S. maltophilia infection. These data suggest that chronic exposure of the respiratory tract of CF patients to S. maltophilia may predispose to tissue invasion, resulting in rising antibody levels to S. maltophilia, pulmonary inflammation and exacerbations.
Chronic infection can be defined in different ways. Multiple studies have used definitions based on number of positive cultures in a given year and shown that chronic, but not intermittent, MRSA and A. fumigatus infection in CF patients are associated with more severe lung disease (6) (7) (8) . The original definition of chronic P. aeruginosa infection in CF patients was based on both the presence of repeated positive respiratory tract cultures and rising P. aeruginosa antibody titers (13) . The group in Leeds subsequently validated a definition of different stages of P. aeruginosa infection based on the percentage of positive cultures and showed that chronic infection was associated with increased disease severity and higher anti-P. aeruginosa antibody results(9). Several investigators have developed serologic assays to detect antibodies to P.
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aeruginosa in CF patients and have shown that higher titers are associated with a worse clinical status, validating their own specific definitions of chronic infection. (14) . (15) . In our study, the microbiologic classification of 2 or more positive cultures in a year as chronic infection was also supported by the selective immune response demonstrated in this group.
The immune response to whole cell S. maltophilia and flagellin in chronically infected patients was approximately two-fold that seen in patients who never had S. maltophilia, suggesting that these patients are truly infected and not simply colonized (16). The serologic response to whole cell S. maltophilia suggests that antibodies may be recognizing epitopes exposed on the bacterial surface (17) . However, only the antibody response to flagellin, the main structural component of flagellae, correlated with lower FEV 1 percent predicted. Flagellae are highly immunogenic and are a common, conserved feature of reference and clinical isolates (10) . Even though S. maltophilia, like P. aeruginosa, may lose its motility in the CF lung over time (18) , antibodies to gene products expressed early in the pathogenesis of infection, such as flagella, persist (13) . In addition, S. maltophilia flagellae are antigenically distinct from those of P. aeruginosa which prevented cross-reactivity with antibodies to this common CF pathogen in our study (10) .
Unlike serologic assays for P. aeruginosa in CF patients, however, this serologic assay did not detect increased antibody levels to S. maltophilia protease (13) (19) . Clinical strains of S. maltophilia are known to produce extracellular alkaline serine protease (11) and protease production may play a role in the development of acute fulminant hemorrhagic pneumonia due to S. maltophilia in immunocompromised patients, for example (20) . In CF patients, however, chronic infection with S. maltophilia may be associated with adaptive, phenotypic changes in the bacteria such as loss of protease production (21) .
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The ability of S. maltophilia to cause infection has been well characterized in vitro. Clinical strains of S. maltophilia have been shown to adhere to, form biofilm on and invade CF airway epithelial cells, albeit at low levels (22) . Clinical S. maltophilia strains have direct cytotoxic effects on a variety of cells (23) and are highly immunostimulatory, eliciting significant IL-8 expression by airway epithelial cells, as well as TNF-α production by macrophages (18, 24) . In two separate studies using a mouse model of pneumonia, S. maltophilia, similar to P. aeruginosa, caused pneumonia with a significant associated inflammatory response, mediated primarily by neutrophils (18, 25) . In comparison to P. aeruginosa, S. maltophilia induced substantially more TNF-α in the murine lung. TNF-α, a potent proinflammatory cytokine that induces neutrophil activation, appears to be important in the pathogenesis of S. maltophilia infection as significantly fewer TNFR1 null mice compared to wild type mice developed pneumonia and bacteremia (18) . Thus, although S. maltophilia does not readily invade, causing sepsis and increased mortality (18) , it does contribute significantly to airway inflammation.
There are few studies, however, investigating the effect of S. maltophilia on clinical outcomes in CF (26-28). The largest epidemiologic study using the CF Foundation National Patient Registry (CFF NPR) found no association between S. maltophilia and short-term survival (3 years) or declining lung function (4, 5) . However, only short term outcomes were assessed, antibiotic treatment of S. maltophilia infection was not taken into account and the effect on pulmonary exacerbations was not determined. In addition, the authors focused primarily on CF patients who were positive at any point in time for S. maltophilia. In order to determine the impact of repeated S. maltophilia detection on lung function, they defined chronic infection as S. maltophilia (approximately 1%/year) may have been too slow to detect the effects of chronic infection on pulmonary function. It is possible that these effects occur predominantly in younger patients before the onset of severe bronchiectasis but our study would be underpowered to detect this due to the small number of pediatric CF patients with chronic S. maltophilia. Chronic S. maltophilia infection, however, was a risk factor for hospitalization for pulmonary exacerbation requiring antibiotic therapy even after adjusting for other factors associated with increased lung disease severity, such as age, P. aeruginosa infection and baseline FEV 1 % predicted. This risk was similar to that seen for P. aeruginosa infection and suggests that S. maltophilia may be playing a role as a pathogen in CF patients.
There are several limitations to this study. Antibodies to whole cell S. maltophilia were measured using the laboratory ATCC strain and strain specific immune responses may not have been detected (29). In addition, serologic responses in CF patients were measured at one point in time with corresponding cross-sectional clinical data. It is possible that higher S. maltophilia antibody levels are associated with lower FEV 1 because chronic S. maltophilia occurs more frequently in sicker patients. Similarly, the increased risk of hospitalization for pulmonary exacerbation in patients with chronic S. maltophilia may simply reflect an increased intensity of therapy in an already severely affected patient population. Antibiotic use is a known risk factor for the isolation of S. maltophilia in the respiratory tract of CF patients (30-33). Increased treatment of pulmonary 12 exacerbations may select out S. maltophilia in the airways of CF patients that are older and have lower lung function. Studies that examine patient cohorts before and after the acquisition of infection are more appropriate in determining the effect of organisms on lung function but require large sample sizes (6, 34) . Therefore, to address the question of whether chronic S. maltophilia directly results in worsening lung function, prospective longitudinal studies, examining the change in immune responses over time and corresponding clinical outcomes, are needed.
In conclusion, this study shows that CF patients with chronic S. maltophilia mount a specific immune response to this organism that is associated with worse lung function, suggesting that this represents a true infection. Whereas previous studies have suggested that S. maltophilia simply colonizes the CF airways and does not affect pulmonary function, we have demonstrated for the first time that chronic S. maltophilia infection is an independent risk factor for pulmonary exacerbation requring hospitalization and antibiotics. Further studies are required to define the role of S. maltophilia in pulmonary exacerbations in CF patients. C.
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Methods
I. Serologic Study
Study Design
This was a cross-sectional study of patients with CF followed at the patients and was performed within 3 months in the remainder.
This study was approved by the Research Ethics Board at the Hospital for Sick Children and St
Michael's Hospital.
Microbiological Classification
All enrolled subjects were classified, using the microbiology database at the Hospital for Sick
Children and St Michael's Hospital, into the following groups according to their respiratory culture status in the previous 12 months based on previously validated definitions (2) maltophilia in a given year or a previous positive culture, 3) Never S. maltophilia: never having a positive sputum or bronchoalveolar culture for S. maltophilia. For the serologic analysis, subjects who never had S. maltophilia were divided into those who had chronic P. aeruginosa (Never S. maltophilia with Chronic P. aeruginosa) and those without chronic P. aeruginosa (Never S. maltophilia without Chronic P. aeruginosa) as it was important to demonstrate that high antibody levels were not due to cross-reaction with antibodies to P. aeruginosa. These definitions were validated against the serologic results.
Antigen Isolation and Purification
Flagellin S. maltophilia flagellin was isolated from the ATCC S.maltophilia strain 13637 known to express flagellae using a protocol described by de Oliveira-Garcia (3). Electron microscopy (EM) of the purified product revealed an abundance of flagellae and sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of the purified protein revealed a predominant band at 38 kDa, corresponding to the molecular weight of S. maltophilia flagellin. The identity of the purified product was further validated by matrix-assisted laser desorption time-of-flight (MALDI-TOF) peptide mass fingerprinting. The concentration of the flagellin was determined using BCA TM Protein Assay (ThermoScientific, Rockford, IL).
Extracellular Alkaline Serine Protease
To identify a clinical strain that produced extracellular alkaline serine protease, proteolytic activity of clinical strains of S. maltophilia from CF patients was screened using a microassay with the chromogenic substrate, azoalbumin (Sigma), as described by Plantner et al. (4) . The clinical strain CFSM51 was then used in the large scale purification of the protease. The extracellular alkaline serine protease of S. maltophilia was purified as previously described (5).
Secreted S. maltophilia serine protease was purified from cell-free culture supernatant by anion exchange chromatography using DEAE-Sephacel (Sigma). Protein fractions were eluted by a linear gradient of 0 -1000 mM NaCl at a flow rate of 1 mL/minute. One hundred 6 mL fractions were collected and assayed for serine protease activity with the specific substrate SucAla-Ala-Pro-Phe-pNA (Sigma) (5) . A single peak of activity was detected and corresponding fractions were pooled together. Pooled fractions were further fractionated by size exclusion chromatography through a Sephacryl S200HR column (Sigma) at a flow rate of 10 drops/minute.
Fractions that demonstrated good serine protease activity as assessed by the Suc-Ala-Ala-ProPhe-pNA assay were pooled. Silver stain gel of the preparation revealed a predominant band at 47 kDa that corresponded to the molecular weight of S. maltophilia protease previously isolated from a clinical strain of S. maltophilia (5) . The protein concentration was determined using the Bradford assay (6) .
Whole Bacterial Cell
S. maltophilia whole bacterial cell was prepared using a modification of a previous protocol (7).
In brief, the ATCC strain 13637 of S. maltophilia was grown overnight at 37°C on a blood agar plate. Colonies were harvested from the plate and resuspended in 10 ml of PBS at an optical density (OD) of 0.08 at 600 nm, corresponding to 10 8 colony forming units (CFU)/ml. The bacteria were then heat-killed at 65°C for 1 hour which was subsequently verified by inoculating a blood agar plate.
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Sera Processing and Serologic Assay
Blood samples were centrifuged at 2500 rpm at 4°C for 10 minutes. The sera were then aliquoted and stored at -80°C for batched serologic studies. Grove, PA) was used as the secondary antibody. After 3 more washes with PBS and 0.05% Tween20 (Sigma, St Louis, MO) and one additional wash with PBS alone, 75 µl of pNPP (Sigma, St Louis, MO) substrate solution was added to each well and incubated for 1 hour at room temperature. To stop hydrolysis, 25 µl of 3M NaOH was added to each well and OD was measured immediately at 405 nm. Results were represented as the ratio of the average serum sample OD to the average OD value of the 2 negative controls (wells with pooled normal human serum) run on the same plate to account for day to day variation in the ELISA (Ratio Units: RU).
The median inter-well variation for ELISA with flagellin, protease and whole bacteria was 7%, 11% and 7% respectively.
Statistical Analysis
Analysis of variance (ANOVA) was used to assess if there was significant difference in mean antibody levels between groups based on the outcome variables. Based on the result, further analysis was performed on the two outcome measures (flagellin and whole bacterial cell) in comparing the chronic group versus all the other groups combined. The correlation between mean antibody levels and forced expiratory volume in 1 second (FEV 1 ) % predicted were done using Pearson's correlation. Multiple regression analysis was also done on FEV 1 % predicted and the mean antibody levels adjusting for age, P. aeruginosa and B. cepacia complex infection.
Statistical analysis was performed using SAS (version 9.1; SAS Institute Inc., Cary, NC). A pvalue of 0.05 or less was considered statistically significant. 
II. Cohort Study
Study Design
This was a retrospective cohort study of patients with CF followed at the Hospital for Sick Patients were included in the study if they had a confirmed diagnosis of CF (1) . Patients were excluded if they could not produce sputum or if they were unable to perform reproducible spirometry. Patients above the age of 50 were excluded as they represent a milder phenotype not typical of the general CF population (8) . Patient data was censored at lung transplantation.
Patients were classified as chronic S. maltophilia, intermittent S. maltophilia and never S. maltophilia (as outlined above) for each year of the study period and the effect on FEV 1 and Page 32 of 36 hospitalization for pulmonary exacerbation was examined in the following year (2) . Patients could thus move from one microbiological classification to another over the study period.
This study was approved by the Research Ethics Board at the Hospital for Sick Children and St
Statistical Analysis
Descriptive statistics, frequency distributions and percentages were calculated for the outcome variables and other covariates of interest. ANOVA was used to assess if there was significant difference in average age, body mass index (BMI) and FEV 1 % predicted at one year in the study between chronic groups. Chi-square test based on one year study of the data was also carried out for assessing the baseline association of gender, pancreatic insufficiency, CF related diabetes (CFRD), P. aeruginosa, mucoid P. aeruginosa and B. cepacia among the chronic group.
Baseline FEV 1 was defined as the best FEV 1 one year before the first observation in the followup period. Two separate regression models were generated as used in a previous study by Amin et al. (2) . In the first model, a hierarchical linear model was generated to look at the effect of chronic S. maltophilia on quarterly FEV 1 allowing for a random effect and slope for each patient.
The second model assessed the effect of chronic S. maltophilia on the number of hospitalizations for pulmonary exacerbation requiring antibiotics using Poisson regression. Multivariable analysis was performed to account for age, gender, body mass index (BMI), baseline FEV 1 , presence of Pseudomonas aeruginosa (current, never, gone), mucoid P. aeruginosa, Burkholderia cepacia complex (current, never, gone), use of antibiotic therapy specific for S. maltophilia, use of inhaled tobramycin, use of oral antibiotics and use of intravenous antibiotics. Multivariable analysis was also performed to account for pancreatic status and CF-related diabetes (CFRD). Statistical analysis was performed using SAS (version 9.1; SAS Institute Inc., Cary, NC). A pvalue of 0.05 or less was considered statistically significant.
Page 34 of 36
